Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The overall aim of this project is to test the hypothesis that the addition of ADT to
metastasis-directed radiotherapy (MDRT) in well-selected PCa patients with oligo-metastatic
disease prolongs the metastases progression-free survival (MPFS) compared to MDRT alone.